^
    18h
    Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer (clinicaltrials.gov)
    P1, N=210, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2033 --> Feb 2029 | Trial primary completion date: Jun 2031 --> Feb 2029
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • SLATE-KRAS
    1d
    Tamoxifen differentially modulates endometrial hyperplasia via wild-type and mutant p53 regulation of the ALKBH5-REG1A axis. (PubMed, Front Oncol)
    These findings establish a mechanistic link between hormonal signaling, p53 allelic status, and m6A-dependent post-transcriptional regulation. Although further in vivo validation is required, disruption of the ALKBH5-REG1A axis may contribute to heterogeneous endometrial responses to tamoxifen, thereby providing a conceptual framework for biomarker-oriented investigation.
    Journal
    |
    ER (Estrogen receptor) • TP53 (Tumor protein P53) • ALKBH5 (AlkB Homolog 5, RNA Demethylase) • REG1A (Lithostathine-1-alpha) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2)
    |
    TP53 mutation • ER positive • TP53 wild-type
    |
    tamoxifen
    4d
    The Noncanonical Role of Hippo Signaling in Cancer. (PubMed, Cold Spring Harb Perspect Biol)
    In this review, we explore the unconventional tumor-suppressive function of YAP/TAZ and the mechanisms through which they inhibit tumor growth, with an emphasis on recent findings in hormone-regulated cancers and ccRCC. Finally, we discuss the therapeutic implications of these emerging findings for cancer treatment.
    Journal
    |
    ER (Estrogen receptor) • AR (Androgen receptor)
    |
    ER positive • AR positive
    6d
    INX-315-01: Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer (clinicaltrials.gov)
    P1/2, N=150, Recruiting, Incyclix Bio | Trial completion date: Jun 2026 --> Sep 2027 | Trial primary completion date: Dec 2025 --> Jul 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Verzenio (abemaciclib) • fulvestrant • INX-315
    6d
    Effect of Aerobic Exercises on Trace Elements in Post-menopausal Women After Radiotherapy (clinicaltrials.gov)
    P=N/A, N=28, Completed, Cairo University | Recruiting --> Completed | Trial completion date: Jan 2024 --> Jan 2026 | Trial primary completion date: Dec 2023 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date • HEOR
    6d
    Ligand Electronics Dictate Geometry, Stability, and Cancer Cell Toxicity in Carbon-Stabilized Gold(III) Macrocycles. (PubMed, Chembiochem)
    σ-donor character of complexes influences geometric distortion, aqueous stability, and up to an order-of-magnitude higher cytotoxicity in triple-negative breast cancer and estrogen receptor-positive models compared to cisplatin. Mechanism of action studies supports acute mitochondrial uncoupling and mtROS production, leading to cell death by this class of compounds. This electronic-structural-biological correlation provides a rare, experimentally validated design principle for Au(III) scaffolds and positions electronically tuned macrocycles as a chemically tractable platform for targeting intracellular pathways.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive
    |
    cisplatin
    6d
    Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER+ HER2- locally-advanced or metastatic breast cancer. (PubMed, Nat Commun)
    In recent clinical trials of metastatic ER+ BC, next-generation SERDs demonstrated clinical activity, and elacestrant received an approval for advanced ESR1-mutant disease. NR tumors instead up-regulate multiple ERα-independent proliferative pathways, such as EGFR/MAPK and Hippo/TEAD, which may represent targetable dependencies in NR disease. Modeling resistance and lineage plasticity in vitro, we find that giredestrant-resistant ER+ BC cell lines exhibit profound shifts in chromatin accessibility, with the transcription factors, FOXA1 and FOXM1, implicated in gene expression of NR-upregulated proliferative pathways.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • FOXA1 (Forkhead Box A1) • FOXM1 (Forkhead Box M1)
    |
    ER positive • HER-2 negative • ESR1 mutation
    |
    Orserdu (elacestrant) • giredestrant (RG6171)
    6d
    A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, Hoffmann-La Roche | Active, not recruiting --> Recruiting
    Enrollment open • Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    ER positive • HER-2 negative • PIK3CA mutation • HER-2 negative + ER positive
    |
    Kisqali (ribociclib) • letrozole • Itovebi (inavolisib)
    6d
    Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer (clinicaltrials.gov)
    P1, N=210, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • SLATE-KRAS
    7d
    Large Language Models Assist in Tumor MDT (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    New trial • Pan tumor